Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.3M Drug Delivery Systems has signed an exclusive licensing agreement with Spirig Pharma, under which Spirig Pharma will utilize one of 3M's immune response modifier (IRM) molecules to further its development of treatment for sun damaged skin.
Subscribe to our email newsletter
In addition, 3M has IRMs available for license in the areas of cancer, asthma/allergy and as vaccine adjuvants.
3M Drug Delivery Systems Vaccine Business Development director Mark Tomai said that the molecule offers potential for treating patients that suffer from a variety of dermatologic conditions
Spirig Pharma CEO Silvio Inderbitzin said that they are excited to expand their franchise of dermatology offerings in the prevention and treatment of sun damage-related skin conditions.
"With 3M’s IRM molecule, we can enhance our portfolio with the help of an experienced partner in drug delivery technologies," Inderbitzin said.